Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst Edward Nash reiterated a Hold rating on Pliant Therapeutics (PLRX) with a price target of $3.00. The company currently holds an analyst consensus of Hold, with a broader price target consensus of $2.50.
Canaccord Genuity analyst Edward Nash reiterated a Hold rating on Pliant Therapeutics today and set a price target of $3.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Nash covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Corcept Therapeutics, and Kymera Therapeutics. According to TipRanks, Nash has an average return of 31.4% and a 55.78% success rate on recommended stocks.
Pliant Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.50.